Pharmacologic treatments for covid-19 patients

Analyses are updated every Friday

Methods

Treatment comparisons

Create and download your forest plots with the most up-to-date data here Forest plots

Access the forest plots for the 269 treatment comparisons .

General characteristics of primary studies

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
NCT02735707, NCT04505774, NCT04359277, NCT04372589
Goligher E, N Engl J Med, 2021
Full text
Full text
Commentary
Mixed Therapeutic heparin Prophylactic anticoagulant RCT Patients with confirmed COVID-19 (severe-critical) admitted to 393 centers in Australia, Brazil, Canada, Ireland, Mexico, Netherlands, New Zealand, Saudi Arabia, UK, USA N=1207
Some concerns
Details

Full description

IRCT20201003048904N2
Abbasi F, 2021
Full text
Commentary
Commentary
Public/non profit Sitagliptin Standard care RCT Patients with suspected or confirmed COVID-19 (unclear severity) admitted to 2 centers in Iran. N=263 N/A

Full description

Spironolactone Standard care
Sitagliptin+Spironolactone Standard care
IRCT20200328046886N1
Abbaspour Kasgari H, J Antimicrob Chemoth, 2020
Full text
Commentary
Public/non profit Sofosbuvir-Daclatasvir+Ribavirin Standard care RCT Patients with confirmed COVID-19 (moderate) admitted to a single center in Iran. N=48
Some concerns
Details

Full description

ISRCTN21085622
Abbass S, 2021
Full text
Commentary
Private Sofosbuvir+Daclatasvir Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 4 centers in Egypt N=120
Some concerns
Details

Full description

Sofosbuvir+Daclatasvir Sofosbuvir+Ravidasvir
Sofosbuvir+Ravidasvir Standard care
NCT04353336
Abd-Elsalam S, Am J Trop Med Hyg, 2020
Full text
Commentary
Public/non profit Hydroxychloroquine Standard care RCT Patients with COVID-19 (mild-severe) admitted to three university hospitals in Egypt. N=194
Some concerns
Details

Full description

NCT04447534
Abd-Elsalam S, Biol Trace Elem Res, 2020
Full text
Commentary
Hydroxychloroquine+Zinc Hydroxychloroquine RCT Patients with confirmed COVID-19 (mild-critical) admitted to 3 centers in Egypt N=191
Some concerns
Details

Full description

NCT04403555
Abd-Elsalam S, J Med Virol, 2021
Full text
Commentary
Not reported/unclear Ivermectin Standard care RCT Patients with confirmed COVID-19 admitted to 2 centers in Egypt N=164
Some concerns
Details

Full description

NCT04753619
Abdulamir A, Ann Med Surg, 2021
Full text
Full text
Commentary
Commentary
No specific funding Niclosamide Standard care RCT Outpatients and inpatients with confirmed COVID-19 (mild-moderate-severe) admitted or treated by 2 centers in Iraq N=150
Some concerns
Details

Full description

NCT04315948; EudraCT
Ader F, DisCoVeRy, Clin Microbiol Infect, 2021
Full text
Commentary
; Commentary
Mixed Lopinavir-Ritonavir Lopinavir-Ritonavir+Interferon beta-1a RCT Patients with confirmed COVID-19 (mild-critical) admitted to 32 centers in France and Luxembourg N=603
Some concerns
Details

Full description

Lopinavir-Ritonavir Hydroxychloroquine
Lopinavir-Ritonavir Standard care
Lopinavir-Ritonavir+Interferon beta-1a Hydroxychloroquine
Lopinavir-Ritonavir+Interferon beta-1a Standard care
Hydroxychloroquine Standard care
NCT04315948, EudraCT2020-000936-23
Ader F, Lancet Infect Dis, 2021
Full text
Full text
Commentary
Public/non profit Remdesivir Standard care RCT Patients with confirmed COVID-19 (mild-critical) admitted to 48 centers in France (39), Belgium (3), Portugal (2), Austria (3), and Luxembourg (1). N=857
Some concerns
Details

Full description

CTRI/2020/04/024775
PLACID
Agarwal A, BMJ, 2020
Full text
Commentary
Public/non profit Convalescent plasma Standard care RCT Patients with confirmed COVID-19 (mild to severe) admitted to 39 centers in India. N=464
Some concerns
Details

Full description

NCT04407130
Ahmed S, 2020
Full text
Commentary
Private Ivermectin+Doxycycline Placebo RCT Patients with confirmed COVID-19 (mild) admitted to hospital in Bangladesh. N=72
Some concerns
Details

Full description

Ivermectin+Doxycycline Ivermectin
Ivermectin Placebo
NCT04350684
Alavi Darazam I (2), Int Immunopharmacol, 2021
Full text
Commentary
No specific funding Lopinavir/ritonavir + hydroxychloroquine + interferon-Beta1a + umifenovir Lopinavir/ritonavir + hydroxychloroquine + interferon Beta-1a RCT Patients with confirmed COVID-19 (severe) admitted to a single center in Iran. N=101
Some concerns
Details

Full description

IRCT20200328046882N1
Alavi-moghaddam M, SSRN, 2021
Full text
Commentary
Public/non profit Sofosbuvir Lopinavir-Ritonavir+Interferon beta-1a RCT Patients with confirmed COVID-19 (severe) admitted to a single center in Iran N=57
Some concerns
Details

Full description

NCT04521309
Ali S, EClinicalMedicine , 2021
Full text
00206-6/fulltext Commentary
Public/non profit Hyperimmune anti-COVID-19 Intravenous Immunoglobulin Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Pakistan N=50
Some concerns
Details

Full description

NCT04356534
AlQahtani M, Sci Rep, 2021
Full text
Commentary
Commentary
Public/non profit Standard care Convalescent plasma RCT Patients with confirmed COVID-19 (severe) admitted to 2 centers in Bahrain N=40
Some concerns
Details

Full description

NCT04573153
Altay O, Adv. Sci., 2021
Full text
Full text
Commentary
Private Combined metabolic cofactor supplementation Placebo RCT Outpatients with confirmed COVID-19 (mild) treated at a single center in Turkey N=93
Some concerns
Details

Full description

EudraCT 2020–001236–10
Aman J, Lancet Respir Med, 2021
Full text
Commentary
Public/non profit Imatinib Placebo RCT Patients with confirmed COVID-19 (severe) admitted to 13 centers in the Netherlands. N=400
Some concerns
Details

Full description

NCT04329923
Amaravadi R, medRxiv, 2021
Full text
Commentary
Commentary
Mixed Hydroxychloroquine Placebo RCT Outpatients with confirmed COVID-19 (symptomatic, mild ) treated by a single center in USA N=34
Some concerns
Details

Full description

IRCT20170207032444N3
Amra B, Research Square, 2021
Full text
Commentary
Commentary
Public/non profit Thalidomide Standard care RCT Patients with suspected or confirmed COVID-19 (severe) admitted to a single center in Iran N=60
High
Details

Full description

NCT04504032
Ananworanich J, Clin Infect Dis, 2021
Full text
Commentary
Commentary
Public/non profit Rivaroxaban Placebo RCT Outpatients with confirmed COVID-19 (mild, symptomatic) treated at 13 centers and one virtual site in the USA. N=497
Some concerns
Details

Full description

NCT02735707
Angus DC, JAMA, 2020
Full text
Commentary
Public/non profit Fixed-dose hydrocortisone Standard care RCT Patients with COVID-19 (severe-critical) admitted to 121 centers in 8 countries N=251
Some concerns
Details

Full description

IRCT20200317046797N4
Ansarin K, BioImpacts, 2020
Full text
Commentary
Public/non profit Bromhexine Standard care RCT Patients with COVID-19 (unclear severity) at a single center in Iran N=78
Some concerns
Details

Full description

NCT02735707
Arabi Y, 2021
Full text
Commentary
Mixed Lopinavir-Ritonavir Standard care RCT Patients with suspected or confirmed COVID-19 (critical) admitted to a multiple centers in Australia, Canada, France, Germany, Ireland, Netherlands, New Zealand, Portugal, Saudi Arabia, UK, and USA N=726
Some concerns
Details

Full description

Lopinavir-Ritonavir Hydroxychloroquine
Lopinavir-Ritonavir Hydroxychloroquine+Lopinavir+Ritonavir
Hydroxychloroquine Hydroxychloroquine+Lopinavir+Ritonavir
Hydroxychloroquine Standard care
Hydroxychloroquine+Lopinavir+Ritonavir Standard care
NCT04412772
ARCHITECTS, Unpublished, 2021
Public/non profit Tocilizumab Placebo RCT Patients with confirmed COVID-19 (critical) admitted to a single center in the USA. N=21
Low
Details

Full description

NCT04716569
Aref ZF, Int J Nanomed, 2021
Full text
Commentary
Public/non profit Ivermectin Standard care RCT Outpatients with confirmed COVID-19 (mild, symptomatic) treated at a single center in Egypt. N=114
Some concerns
Details

Full description

NCT04345523
Avendano-Sola C, J Clin Invest, 2021
Full text
Full text
Commentary
Public/non profit Convalescent plasma Standard care RCT Patients with confirmed COVID-19 (mild-moderate) admitted to 27 centers in Spain N=350
Some concerns
Details

Full description

ISRCTN40302986
Babalola OE, IVERCOVID, QJM, 2021
Full text
Commentary
Commentary
Private Ivermectin 6mg Ivermectin 12mg RCT Patients with confirmed COVID-19 (mild-moderate) admitted to a single center in Nigeria N=62
Some concerns
Details

Full description

Ivermectin 6mg Lopinavir-Ritonavir
Ivermectin 12mg Lopinavir-Ritonavir
NCT04346446
Bajpai M, medRxiv, 2020
Full text
Commentary
Commentary
No specific funding Convalescent plasma Fresh frozen plasma RCT Patients with confirmed COVID-19 (severe) admitted to a single center in India N=31
Some concerns
Details

Full description

NCT04375098
Balcells M, PLoS Med, 2021
Full text
Commentary
Public/non profit Early Convalescent plasma Late Convalescent plasma RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a single centre in Chile. N=58
High
Details

Full description

NCT04542694
Balykova L, Infektsionnye bolezn, 2020
Full text
Commentary
Private Favipiravir Standard care RCT Patients with confirmed COVID-19 (moderate) admitted to 5 centers in Russia N=200
Some concerns
Details

Full description

NCT04321616
Barratt-Due A, Ann Intern Med, 2021
Full text
Full text
Commentary
Mixed Remdesivir Standard care RCT Patients with confirmed COVID-19 (unclear severity) admitted to 23 centers in Norway N=101
Low
Details

Full description

NCT04321616
Barratt-Due A, Ann Intern Med, 2021
Full text
Full text
Commentary
Mixed Hydroxychloroquine Standard care RCT Patients with confirmed COVID-19 (unclear severity) admitted to 23 centers in Norway N=108
Some concerns
Details

Full description

NCT04353596
Bauer A, Lancet , 2021
Full text
Commentary
Public/non profit Continue ARB/ACEI Discontinue ARB/ACEI RCT Outpatients and inpatients with confirmed COVID-19 (mild-severe) admitted to 35 centers in Austria and Germany N=216
Some concerns
Details

Full description

NCT04348656
Begin P, medRxiv, 2021
Full text
Commentary
Commentary
Public/non profit Convalescent plasma Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 72 centers in Canada, USA and Brazil. N=940
Some concerns
Details

Full description

NCT04280705
Beigel JH, N Engl J Med, 2020
Full text
Commentary
Public/non profit Remdesivir Placebo RCT Patients with confirmed COVID-19 (mild-critical) admitted to 60 centers in 10 countries N=1062
Some concerns
Details

Full description

NCT04391127
Beltran-Gonzalez J, 2021
Full text
Commentary
Commentary
Public/non profit Ivermectin Placebo RCT Patients with suspected or confirmed COVID-19 (moderate/severe) admitted to a single center in Mexico N=106
Some concerns
Details

Full description

Hydroxychloroquine Placebo
Ivermectin Hydroxychloroquine
NCT04344535
Bennett-Guerrero, E, Crit Care Med, 2021
Full text
Commentary
Commentary
Private Convalescent plasma Standard plasma RCT Patients with confirmed COVID-19 (mild-critical) admitted to a single center in USA. N=74
Some concerns
Details

Full description

CTRI/2020/12/029855
Bhushan S, Int J Infect Dis, 2021
Full text
Commentary
Private Pegylated Interferon alpha-2b Standard care RCT Patients with confirmed COVID-19 (severe) admitted to 20 centers in India. N=250
Some concerns
Details

Full description

NCT04429711
Biber A, medRxiv, 2021
Full text
Commentary
Commentary
No specific funding Ivermectin Placebo RCT Outpatients with confirmed COVID-19 (mild) treated by multiple centers in Israel N=116
Some concerns
Details

Full description

NCT04486508
Bikdeli B, Thromb Haemost, 2021
Full text
Full text
Commentary
Commentary
Commentary
Mixed Standard-Dose prophylactic anticoagulation Intermediate-Dose prophylactic anticoagulation RCT Patients with confirmed COVID-19 (critical) admitted to 10 centers in Iran N=598
Some concerns
Details

Full description

NCT04348409
Blum VF, EClinicalMedicine, 2021
Full text
Full text
Commentary
Private Nitazoxanide Placebo RCT Patients with confirmed COVID-19 (mild/moderate) admitted to 6 centers in Brazil. N=50
Some concerns
Details

Full description

NCT04323527
Borba MGS, JAMA Netw Open, 2020
Full text
Commentary
Public/non profit Chloroquine 450mg Chloroquine 600mg RCT Patients with Severe/Critical respiratory syndrome secondary to SARS-CoV-2 infection treated in a single center in Brazil. N=81
Low
Details

Full description

Forest plots
N/A
Borges M, Revista Universidad,, 2021
Full text
Commentary
Not reported/unclear Methisoprinol Standard care RCT Outpatients with confirmed COVID-19 (symptomatic) treated at home in Ecuador N=60 N/A

Full description

NCT04392973
Bosaeed M, Infect Dis Ther, 2021
Full text
Commentary
Public/non profit Favipiravir+Hydroxychloroquine Standard care RCT Patients with confirmed COVID-19 (mild to critical) admitted to 9 centers in Saudi Arabia N=268
Some concerns
Details

Full description

NCT04329832
Brown SM, Ann Am Thorac Soc, 2020
Full text
Commentary
Public/non profit Hydroxychloroquine Azithromycin RCT Patients with confirmed COVID-19 (mild-critical) admitted to 13 centers in the USA N=85
Some concerns
Details

Full description

ISRCTN86534580 ; EudraCT 2020-001209-22
Butler C, Lancet , 2021
Full text
Commentary
Public/non profit Azithromycin Standard care RCT Outpatients with suspected or confirmed COVID-19 (mild) recruited in the community in the UK N=540
High
Details

Full description

ISRCTN86534580
Butler C, Lancet Respir Med, 2021
Full text
Commentary
Public/non profit Doxycycline Standard care RCT Outpatients with suspected or confirmed COVID-19 (symptomatic, mild) recruited in the community in the UK N=827
Some concerns
Details

Full description

NCT04860284
Byakika-Kibwika P, Research square , 2021
Full text
Commentary
Commentary
Public/non profit Hydroxychloroquine Standard care RCT Outpatients with confirmed COVID-19 (asymptomatic and symptomatic, mild) isolated at a single center in Uganda. N=105
Some concerns
Details

Full description

NCT04729491
Cadegiani F, Cureus, 2021
Full text
Commentary
Commentary
Commentary
No specific funding Dutasteride Placebo RCT Outpatients with confirmed COVID-19 (mild) treated by 5 centers in Brazil N=130
Some concerns
Details

Full description

NCT04728802
Cadegiani F, medRxiv, 2021
Full text
Commentary
Commentary
Private Proxalutamide Placebo RCT Patients with confirmed COVID-19 (mild-severe) admitted to 8 centers in Brazil. N=645
Low
Details

Full description

NCT04446429
Cadegiani FA, Cureus, 2021
Full text
Commentary
Commentary
Mixed Proxalutamide Placebo RCT Male outpatients with confirmed COVID-19 (mild) treated at 2 centers in Brazil. N=262
High
Details

Full description

ChiCTR2000029308
Cao B, N Engl J Med, 2020
Full text
Commentary
Commentary
Mixed Lopinavir-Ritonavir Standard care RCT Patients with confirmed COVID-19 (severe) admitted to a single center in China. N=199
Some concerns
Details

Full description

ChiCTR-OPN-200002958
Cao Y, J Allergy Clin Immun, 2020
Full text
Commentary
Public/non profit Ruxolitinib Vitamin C RCT Patients with COVID-19 (severe) admitted to 3 centers in China. N=43
Some concerns
Details

Full description

NCT04362813; EudraCT 2020-001370-30
Caricchio R, JAMA, 2021
Full text
Commentary
Private Canakinumab Placebo RCT Patients with suspected or confirmed COVID-19 (mild-severe) admitted to 39 centers in France, Italy, Russia, Spain, UK and USA. N=454
Low
Details

Full description

NCT04473170
Carmenate Y, Research square , 2021
Full text
Commentary
Commentary
Private Autologous Non-Hematopoietic Peripheral Blood Stem Cells Standard care RCT Patients with confirmed COVID-19 (mild-critical) admitted to 4 centers in United Arab Emirates. N=143
High
Details

Full description

NCT04322123
Cavalcanti AB, N Engl J Med, 2020
Full text
Commentary
Mixed Hydroxychloroquine Standard care RCT Patients with suspected or confirmed COVID-19 (mild-moderate) admitted to 55 centers in Brazil N=667
Some concerns
Details

Full description

Hydroxychloroquine + Azithromycin Standard care
Hydroxychloroquine + Azithromycin Hydroxychloroquine
NCT04390022
Chaccour C, EClinicalMedicine, 2021
Full text
Commentary
Mixed Ivermectin Placebo RCT Outpatients with confirmed COVID-19 (mild) attending the emergency room at a single center in Spain N=24
Some concerns
Details

Full description

NCT04784481
Chahla R, Research Square, 2021
Full text
Commentary
Public/non profit Ivermectin Standard care RCT Outpatients with confirmed COVID-19 (mild) treated by multiple centers in Argentina. N=254
Some concerns
Details

Full description

ChiCTR2000030254
Chen C, Front Pharmacol, 2021
Full text
Full text
Commentary
Public/non profit Favipiravir Umifenovir RCT Patients with confirmed COVID-19 (moderate-critical) admitted to 3 centers in China N=240
Some concerns
Details

Full description

NCT04384380
Chen CP, Plos one, 2020
Full text
Full text
Commentary
Mixed Hydroxychloroquine Standard care RCT Patients with confirmed COVID-19 (mild-moderate) admitted to 11 centers in Taiwan N=33
Some concerns
Details

Full description

NCT04261517
Chen J, Journal of Zhejiang , 2020
Full text
Commentary
Public/non profit Hydroxychloroquine Standard care RCT Patients with confirmed COVID-19 (unclear severity) admitted to a single center in China N=30
High
Details

Full description

NCT04252274
Chen J, Open Forum Infect Di, 2020
Full text
Commentary
Public/non profit Darunavir/cobicistat Standard care RCT Patients with COVID-19 (moderate) admitted to a single center in China N=30
High
Details

Full description

ChiCTR2000030054
Chen L, medRxiv, 2020
Full text
Commentary
Public Hydroxychloroquine Chloroquine RCT Patients with confirmed COVID-19 (mild, moderate) admitted to a single center in China N=67
High
Details

Full description

Chloroquine Standard care
Hydroxychloroquine Standard care
NCT04427501
Chen P, N Engl J Med, 2020
Full text
Commentary
Private Bamlanivimab (LY-CoV555) Placebo RCT Outpatients with confirmed COVID-19 (mild) treated at 41 centers in USA N=467
Low
Details

Full description

ChiCTR2000029559
Chen Z, medRxiv, 2020
Full text
Commentary
Commentary
Public/non profit Hydroxychloroquine Standard care RCT Patients with confirmed COVID-19 (moderate) admitted to a single center in China. N=62
Some concerns
Details

Full description

ChiCTR2000030007
Cheng L, JAMA Intern Med, 2020
Full text
Commentary
Mixed rhG-CSF Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 3 centers in China N=200
Some concerns
Details

Full description

NCT04434144
Chowdhury ATMM, EJMO, 2021
Full text
Commentary
Commentary
No specific funding Ivermectin+Doxycycline Hydroxychloroquine+Azithromycin RCT Outpatients with confirmed COVID-19 (asymptomatic, mild) treated by a single center in Bangladesh N=125
High
Details

Full description

NCT04377711
Clemency B, medRxiv, 2021
Full text
Commentary
Commentary
Private Ciclesonide Standard Care RCT Outpatients with confirmed COVID-19 (mild, symptomatic) treated by 10 centers in the USA. N=400
Some concerns
Details

Full description

NCT04338009
Cohen J, Lancet Respir Med, 2021
Full text
Commentary
Commentary
Mixed Continue ARB/ACEI Discontinue ARB/ACEI RCT Patients with suspected and confirmed COVID-19 (unclear severity) admitted to 20 centers in Argentina, Bolivia, Canada, Mexico, Peru, Sweden, USA N=152
Some concerns
Details

Full description

NCT04324073
CORIMUNO-SARI, Unpublished, 2021
Public/non profit Standard care Sarilumab RCT Patients with suspected or confirmed COVID-19 (moderate-severe) admitted to multiple centers in France. N=*
Low
Details

Full description

NCT04331808
CORIMUNO-TOCI-2 (ICU), Unpublished, 2021
Public/non profit Standard care Tocilizumab RCT Patients with suspected or confirmed COVID-19 (severe-critical) admitted to multiple centers in France. N=*
Low
Details

Full description

EudraCT202000193437
Corral-Gudino L, medRxiv, 2020
Full text
Commentary
No specific funding Methylprednisolone Standard care RCT Patients with COVID-19 (severe) admitted to 5 centers in Spain N=64
High
Details

Full description

NCT04330638
COV-AID, Unpublished, 2021
Public/non profit Tocilizumab Standard care RCT Patients with suspected or confirmed COVID-19 (severe-critical) admitted to 16 centers in Belgium N=153
Low
Details

Full description

NCT04479358
COVIDOSE-2, Unpublished, 2021
Public/non profit Tocilizumab Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to multiple centers in the USA N=28
Low
Details

Full description

NCT04577534
COVIDSTORM, Unpublished, 2021
Not reported/unclear Standard care Tocilizumab RCT Patients with confirmed COVID-19 (severe) admitted to a single center in Finland. N=39
Low
Details

Full description

NCT04435717
COVITOZ-01, Unpublished, 2021
Public/non profit Standard care Tocilizumab RCT Patients with suspected or confirmed COVID-19 (mild-moderate-severe) admitted to a single center in Spain. N=26
Low
Details

Full description

NCT04399980, NCT04463004, NCT04492514
Cremer P, Lancet Rheumatol, 2021
Full text
Commentary
Private Mavrilimumab Placebo RCT Patients with confirmed COVID-19 (moderate/severe) admitted to 7 centers in the USA N=40
Some concerns
Details

Full description

NCT04365153
Cremer P, The three C study, 2021
Full text
Commentary
Private Canakinumab 600mg Placebo RCT Patients with confirmed COVID-19 (mild-critical) admitted to 2 centers in the USA N=45
Some concerns
Details

Full description

Canakinumab 600mg Canakinumab 300mg
Canakinumab 300mg Placebo
RPCEC00000317
Cruz LR, ACS Pharmacol. Trans, 2020
Full text
Commentary
Commentary
Mixed CIGB-325 Standard care RCT Patients with confirmed COVID-19 (asymptomatic-severe) admitted to a single center in Cuba N=20
Some concerns
Details

Full description

NCT04351295
Dabbous H, Arch Virol, 2021
Full text
Commentary
Not reported/unclear Favipiravir Chloroquine RCT Patients with confirmed COVID-19 (unclear severity) admitted to 2 centers in Egypt N=96
Some concerns
Details

Full description

NCT04521400
Darazam I, Int Immunopharmacol, 2021
Full text
Full text
Commentary
Public/non profit High dose Interferon-β 1a Low dose Interferon-β 1a RCT Patients with T-PCR and/or chest CT confirmed COVID-19 (moderate-severe) admitted to a single center in Iran. N=168
Some concerns
Details

Full description

NCT04343768
Darazam IA, COVIFERON, 2021
Full text
Commentary
; Commentary
No specific funding Interferon beta-1b Standard care RCT Patients with confirmed COVID-19 (severe) admitted to a single center in Iran. N=60
Some concerns
Details

Full description

Interferon beta-1a Standard care
Interferon beta-1b Interferon beta-1a
IRCT20190727044343N1
Davoodi L, Int J Clin Pract, 2020
Full text
Commentary
Public/non profit Febuxostat Hydroxychloroquine RCT Outpatients with COVID-19 (mild-moderate) treated at a single center in Iran N=60
Some concerns
Details

Full description

IRCT20100228003449N28
Davoudi-Monfared E, Antimicrob Agents Ch, 2020
Full text
Commentary
Private Interferon beta-1a Standard care RCT Patients with COVID-19 (moderate to critical) admitted to a single center in Iran. N=92
High
Details

Full description

NCT04326790
Deftereos S, JAMA, 2020
Full text
Commentary
Private Colchicine Standard care RCT Patients with COVID-19 (moderate-severe) admitted to 16 centers in Greece. N=110
Some concerns
Details

Full description

RPCEC00000309
Delgado-Enciso I, Exp Ther Med, 2021
Full text
Full text
Commentary
Commentary
Mixed Neutral electrolyzed saline Standard care RCT Outpatients with confirmed COVID-19 (ambulatory, mild) treated at home in Mexico. N=*
Some concerns
Details

Full description

NCT02517489
Dequin P-F, JAMA, 2020
Full text
Commentary
Public/non profit Hydrocortisone Placebo RCT Patients with COVID-19 (severe-critical) admitted to 9 centers in France N=149
Some concerns
Details

Full description

NCT02735707
Derde L, REMAP-CAP, 2021
Full text
Commentary
Commentary
Mixed Tocilizumab Standard care RCT Patients with suspected or confirmed COVID-19 (moderate to critical) admitted to 133 centers in 9 countries N=2253
Some concerns
Details

Full description

Sarilumab Standard care
Anakinra Standard care
NCT04861298
Di Pierro F, Int J Gen Med, 2021
Full text
Commentary
Private Quercetin Standard care RCT Outpatients with confirmed COVID-19 (mild) treated at a single center in Pakistan N=42
Some concerns
Details

Full description

NCT04457609
Dilogo IH, Stem Cells Transl Med, 2021
Full text
Commentary
Public/non profit Umbilical cord mesenchymal stromal cell infusion Placebo RCT Patients with confirmed COVID-19 (critical) admitted to a 4 centers in Indonesia N=40 N/A

Full description

jRCTs041190120
Doi Y, Antimicrob Agents Ch, 2020
Full text
Commentary
Mixed Favipiravir Favipiravir RCT Patients with confirmed COVID-19 (asymptomatic-mild-moderate) admitted to multiple centers in Japan N=88
Some concerns
Details

Full description

NCT04427501
Dougan M, N Engl J Med, 2021
Full text
Commentary
Private LY-CoV555+LY-CoV016 Placebo RCT Outpatients with confirmed COVID-19 (mild-moderate) treated at multiple centers in USA. N=1035
Some concerns
Details

Full description

NCT04244591
Du, Unpublished, 2020
Public/non profit Methylprednisolone Standard care RCT Patients with confirmed COVID-19 (severe-critical) admitted to multiple centers in China N=47
Some concerns
Details

Full description

NCT04355936
Duarte M, EClinicalMedicine, 2021
Full text
Commentary
Mixed Telmisartan Standard care RCT Patients with confirmed COVID-19 (unclear severity) admitted to 2 centers in Argentina N=162
Some concerns
Details

Full description

NCT04325893
Dubee V, Clin Microbiol Infec, 2021
Full text
Commentary
Commentary
Public/non profit Hydroxychloroquine Placebo RCT Patients with confirmed COVID-19 (mild-moderate) admitted to 34 centers in France and Monaco. N=250
Some concerns
Details

Full description

IRCT20200404046947N1
Edalatifard M, Eur Respir J, 2020
Full text
Commentary
Public/non profit Intravenous Methylprednisolone pulse Standard care RCT Patients with confirmed COVID-19 (severe) admitted to two centers in Iran N=68
Some concerns
Details

Full description

N/A
El-Bendary M, Expert Rev Anti-Infe, 2021
Full text
Commentary
No specific funding Sofosbuvir+Daclatasvir Standard care RCT Patients with confirmed COVID-19 (mild-moderate-severe) treated by or admitted to 3 centers in Egypt. N=174
Some concerns
Details

Full description

N/A
Elamir YM, Bone, 2021
Full text
Commentary
Not reported/unclear Calcitriol Standard care RCT Patients with confirmed COVID-19 (mild-severe) admitted to 3 centers in USA. N=50
Some concerns
Details

Full description

NCT04530422
Elgohary M, medRxiv, 2021
Full text
Commentary
Commentary
Not reported/unclear Sofosbuvir+Ledipasvir Standard care RCT Patients with confirmed COVID-19 (moderate) admitted to a single center in Egypt N=250
Some concerns
Details

Full description

NCT04366908
Entrenas Castillo M, J Steroid Biochem Mo, 2020
Full text
Commentary
Public/non profit Calcifediol Standard care RCT Patients with confimed COVID-19 (moderate-severe) admitted to a single center in Spain N=76
Some concerns
Details

Full description

NCT04602000; EudraCT: 2020-003369-20; CRIS: KCT000
Eom J, 2021
Full text
Commentary
Commentary
Private CT-P59 40mg/kg Placebo RCT Outpatients with confirmed COVID-19 (mild symptomatic) treated at 23 centers in South Korea, Romania, Spain and USA N=327
Low
Details

Full description

CT-P59 40mg/kg CT-P59 80mg/kg
CT-P59 80mg/kg Placebo
RPCEC00000307
Esquivel-Moynelo I, medRxiv, 2020
Full text
Commentary
Public/non profit IFN alpha2b+IFN gamma Interferon alpha2b RCT Patients with confirmed COVID-19 (ambulatory, mild) admitted to a single center N=79
High
Details

Full description

NCT02735707
Estcourt L, medRxiv, 2021
Full text
Commentary
Mixed Standard care Convalescent plasma RCT Patients with confirmed COVID-19 (severe-critical) admitted to 129 centers in Australia, Canada, UK, USA N=2000
Low
Details

Full description

IRCT20151227025726N23
Fakharian A, Int Immunopharmacol, 2021
Full text
Commentary
Public/non profit Adalimumab Standard care RCT Patients with confirmed COVID-19 (severe-critical) admitted to a single center in Iran N=68
Some concerns
Details

Full description

IRCT20200406046963N1
Farahani R, Research Square, 2020
Full text
Commentary
Public/non profit Intravenous Methylprednisolone pulse+Prednisolone Standard care RCT Patients with COVID-19 (severe) admitted to a single center in Iran N=29 N/A

Full description

NCT04354259
Feld JJ, Lancet Respir Med, 2021
Full text
Commentary
Commentary
Mixed Peginterferon Lambda-1 Placebo RCT Outpatients with confirmed COVID-19 (mild) tested at 6 centers in Canada N=60
Some concerns
Details

Full description

NCT04405570
Fischer W, 2021
Full text
Commentary
Commentary
Mixed Molnupiravir 400mg Placebo RCT N=202
High
Details

Full description

Molnupiravir 800mg Placebo
Molnupiravir 200mg Placebo
ISRCTN40580903, EudraCT 2020-001684-85
Fisher B, CATALYST, 2021
Full text
Commentary
Commentary
Public/non profit Namilumab Standard care RCT Patients with suspected or confirmed COVID-19 (moderate-critical) admitted to nine centers in the UK N=146
Some concerns
Details

Full description

Infliximab Standard care
NCT04343963
Fragoso-Saavedra S, medRxiv, 2021
Full text
Commentary
Commentary
Public/non profit Pyridostigmine Placebo RCT Patients with confirmed COVID-19 (severe) admitted to 2 centers in Mexico. N=188
Some concerns
Details

Full description

ChiCTR2000030262
Fu W, EClinicalMedicine, 2020
Full text
Commentary
Public/non profit Interferon kappa+TFF2 Standard care RCT Patients with confirmed COVID-19 (moderate) admitted to a single center in China N=80
Some concerns
Details

Full description

NCT04321278
Furtado RHM, Lancet, 2020
Full text
Mixed Azithromycin + Hydroxychloroquine Hydroxychloroquine RCT Patients with suspected or confirmed COVID-19 (moderate-critical) admitted to 57 centers in Brazil N=447
Some concerns
Details

Full description

NCT04359095
Gaitan-Duarte H, 2021
Full text
Commentary
Commentary
Public/non profit Tenofovir/Emtricitabine Standard care RCT Patients with suspected or confirmed COVID-19 (mild-critical) admitted to six centers in Colombia N=649
Some concerns
Details

Full description

Colchicine+Rosuvastatin Standard care
Emtricitabine/tenofovir+Colchicine+Rosuvastatin Standard care
RBR-8h7q82
Galan L ,Pathog Glob Health, 2021
Full text
Commentary
Public/non profit Ivermectin Hydroxychloroquine RCT Patients with serology or RT-PCR confirmed COVID-19 (moderate-critical) admitted to a single center in Brazil. N=168 N/A

Full description

Ivermectin Chloroquine
Hydroxychloroquine Chloroquine
RBR-8969zg
Garcia de Alencar JC, CID, 2020
Full text
Commentary
Public/non profit N-acetylcysteine Placebo RCT Patients with COVID-19 (mild-severe) admitted to a single center in Brazil N=140 N/A

Full description

NCT04340557
Geriak M, Infect Dis Ther, 2021
Full text
Commentary
Private Losartan Standard care RCT Patients with confirmed COVID-19 (moderate) admitted to 3 centers in USA. N=32
High
Details

Full description

IRCT20200523047550N1
Ghaderkhani S, Research Square, 2021
Full text
Commentary
Commentary
Public/non profit Hydroxychloroquine+Umifenovir Hydroxychloroquine RCT Outpatients with suspected or confirmed COVID-19 (mild-moderate) treated by a single center in Iran N=56 N/A

Full description

NCT04365127
Ghandehari S, SSRN, 2020
Full text
Commentary
Commentary
Private Progesterone Standard care RCT Patients with confirmed COVID-19 (mild-severe) admitted to a single center in the USA. N=42
Some concerns
Details

Full description

IRCT20200318046812N2
Ghanei M, 2021
Full text
Commentary
Public/non profit Prednisolone+Azithromycin+Naproxen Lopinavir+Ritonavir RCT Patients with confirmed COVID-19 (severe) admitted to 6 centers in Iran. N=352
Some concerns
Details

Full description

Azithromycin+Naproxen Lopinavir+Ritonavir
Prednisolone+Azithromycin+Naproxen Azithromycin+Naproxen
NCT04342182
Gharbharan A, Nat Commun, 2021
Full text
Commentary
Mixed Convalescent plasma Standard care RCT Patients with confirmed COVID-19 (moderate-critical) admitted to 14 centers in the Netherlands N=86
Some concerns
Details

Full description

IRCT20200501047259N1
Gharebaghi N, BMC Infect Dis., 2020
Full text
Commentary
Public/non profit Intravenous Immunoglobulin Placebo RCT Patients with confirmed COVID-19 (severe) admitted to a single center in Iran N=59 N/A

Full description

CTRI/2020/07/026791
Ghati N, Removed from SSRN
Full text
Commentary
Commentary
No specific funding Atorvastatin Standard care RCT Patients with confirmed COVID-19 (mild-severe) admitted to a single center in India N=900
Some concerns
Details

Full description

Atorvastatin Aspirin
Atorvastatin Atorvastatin+Aspirin
Aspirin Standard care
Aspirin Atorvastatin+Aspirin
Atorvastatin+Aspirin Standard care
NCT04292899
Goldman JD, N Engl J Med, 2020
Full text
Results in clinicaltrials.gov
Full text
Commentary
Commentary
Private Remdesivir 5 days Remdesivir 10 days RCT Patients with confirmed COVID-19 (moderate to critical) admitted to 55 centers across 5 countries. N=402
Some concerns
Details

Full description

Forest plots
ISRCTN59048638
Gonzalez-Ochoa AJ , Thromb Haemost, 2021
Full text
Commentary
Commentary
Private Sulodexide Placebo RCT Outpatients with confirmed COVID-19 (mild) of a single center in Mexico N=312
Some concerns
Details

Full description

NCT02735707
Gordon AC, REMAP-CAP, 2021
Full text
Commentary
Commentary
Mixed Tocilizumab Standard care RCT Patients with confirmed or suspected COVID-19 (severe-critical) admitted to 113 centers in Australia, Ireland, the Netherlands, New Zealand, Saudi Arabia, UK. N=826
Some concerns
Details

Full description

Sarilumab Standard care
NCT04427501
Gottlieb R, BLAZE-1, 2021
Full text
Commentary
Commentary
Private LY-CoV555 700 mg Placebo RCT Outpatients with COVID-19 (mild ambulatory) treated at 49 centers in USA N=592
Some concerns
Details

Full description

LY-CoV555 2800 mg Placebo
LY-CoV555 7000 mg Placebo
LY-CoV555+LY-CoV016 Placebo
NCT04469114
Guimaraes P, N Engl J Med, 2021
Full text
Commentary
Private Tofacitinib Placebo RCT Patients with confirmed COVID-19 (mild-moderate-severe) admitted to 15 centers in Brazil N=289
Low
Details

Full description

NCT04321096 ; EudraCT Number: 2020001,20042
Gunst J, EClinicalMedicine, 2021
Full text
Commentary
Private Camostat Mesilate Placebo RCT Patients with confirmed COVID-19 (mild-severe) admitted to 9 centers in Denmark and Sweden. N=208
Some concerns
Details

Full description

NCT04545060
Gupta A, medRxiv, 2021
Full text
Commentary
Private Sotrovimab Placebo RCT Outpatients with confirmed COVID-19 (mild)and at high risk for Covid-19 progression, treated by 37 centers in the USA, Canada, Brazil, and Spain. N=583
Low
Details

Full description

N/A
Guvenmez O, J Popul Ther Clin Ph, 2020
Full text
Commentary
No specific funding Lincomycin Azithromycin RCT Patients with confirmed COVID-19 (moderate) admitted to a single center in Turkey N=24
Some concerns
Details

Full description

N/A
Hamed D M, J Infect Public Heal, 2021
Full text
Commentary
No specific funding Methylprednisolone Methylprednisolone +Tocilizumab RCT Patients with confirmed COVID-19 (severe) admitted to a single center in Dubai. N=49
Some concerns
Details

Full description

NCT04414124
Haran J, medRxiv, 2021
Full text
Commentary
Commentary
Private KB109 Standard care RCT Outpatients with confirmed COVID-19 (mild) treated by 16 centers in the USA. N=350
Some concerns
Details

Full description

NCT04591600
Hashim A, medRxiv, 2020
Full text
Commentary
Commentary
Public/non profit Ivermectin+Doxycycline Standard care RCT Outpatients and inpatients with COVID-19 (unclear severity) treated at 2 centers in Iraq N=140
High
Details

Full description

NCT04331808
Hermine O, JAMA Intern Med, 2020
Full text
Commentary
Public/non profit Tocilizumab Standard care RCT Patients with COVID-19 (moderate-severe) admitted to nine centers in France N=131
Some concerns
Details

Full description

NCT04476979
Hermine O, SSRN, 2021
Full text
Commentary
Commentary
Public/non profit Tocilizumab + Dexamethasone Dexamethasone RCT Patients with confirmed COVID-19 (moderate) admitted to 25 centers in France and French Guyana. N=453
Some concerns
Details

Full description

NCT04315896
Hernandez-Cardenas C, medRxiv, 2021
Full text
Commentary
Commentary
Mixed Hydroxychloroquine Placebo RCT Patients with RT-PCR confirmed COVID-19 (severe-critical) admitted to 3 centers in Mexico N=214
Some concerns
Details

Full description

NCT04381962
Hinks T, Lancet Respir Med, 2021
Full text
00263-0/fulltext Commentary
Commentary
Mixed Azithromycin Standard care RCT Outpatients with suspected or confirmed COVID-19 (mild) treated at 19 centers in the UK. N=295
Some concerns
Details

Full description

NCT04377750
HMO-0224-20, Unpublished, 2021
Public/non profit Placebo Tocilizumab RCT Patients with confirmed COVID-19 (severe-critical) admitted to multiple centers in Israel. N=54
High
Details

Full description

NCT04682873
Holubovska O, medRxiv, 2021
Full text
Commentary
Commentary
Mixed Enisamium Placebo RCT Patients with confirmed COVID-10 (mild/moderate) admitted to 15 centers in Ukraine N=* N/A

Full description

NCT04381936, EudraCT 2020-001113-21, ISRCTN5018967
Horby P(2), medRxiv, 2021
Full text
Commentary
Commentary
Mixed Casirivimab+Imdevimab (REGN-COV2) Standard care RCT Patients with suspected or confirmed COVID-19 (mild-critical) admitted to 127 centers in the UK N=9785
Some concerns
Details

Full description

NCT04381936
Horby P, Lancet, 2020
Full text
Commentary
Mixed Lopinavir-Ritonavir Standard care RCT Patients with suspected or confirmed COVID-19 (mild-critical) admitted to 163 centers in the UK N=5040
Some concerns
Details

Full description

NCT04381936 ; ISRCTN (50189673)
Horby P, Lancet, 2021
Full text
Commentary
Commentary
Mixed Azithromycin Standard care RCT Patients with suspected or confirmed COVID-19 (mild to critical) admitted to 176 centers in the UK N=7763
Some concerns
Details

Full description

NCT04381936, ISRCTN50189673
Horby P, Lancet, 2021
Full text
Commentary
Commentary
Public/non profit Tocilizumab Standard care RCT Patients with suspected or confirmed COVID-19 (moderate-critical) admitted to 131 centers in the UK N=4116
Some concerns
Details

Full description

NCT04381936; EudraCT 2020-001113-21; ISRCTN5018967
Horby P, Lancet, 2021
Full text
Commentary
Commentary
Public/non profit Convalescent plasma Standard care RCT Patients with suspected or confirmed COVID-19 (mild-moderate-severe-critical) admitted to 177 centers in the UK. N=11558
Some concerns
Details

Full description

NCT04381936 ; ISRCTN50189673
Horby P, medRxiv, 2021
Full text
Commentary
Commentary
Mixed Colchicine Standard care RCT Patients with suspected or confirmed COVID-19 (mild-critical) admitted to 177 centers in the UK, 2 centers in Indonesia, and 2 centers in Nepal N=11340
Some concerns
Details

Full description

NCT04381936; ISRCTN50189673
Horby P, medRxiv, 2021
Full text
Commentary
Commentary
Mixed Aspirin Standard care RCT Patients with suspected and confirmed COVID-19 (mild-critical) admitted to 177 centers in the UK, 2 centers in Indonesia and 2 centers in Nepal N=14892
Some concerns
Details

Full description

NCT04381936
Horby P, N Engl J Med, 2020
Full text
Commentary
Mixed Hydroxychloroquine Standard care RCT Patients with COVID-19 (mild-critical) admitted to 176 centers in the UK N=4716
Some concerns
Details

Full description

NCT04381936
RECOVERY Trial
Horby P, N Engl J Med, 2021
Full text
Commentary
Mixed Dexamethasone Standard care RCT Patients with suspected and confirmed COVID-19 (mild-moderate-critical) admitted to 176 centers in the UK N=6425
Some concerns
Details

Full description

Forest plot
(sub group)
ChiCTR2000029387
Huang YQ, Front Pharmacol, 2020
Full text
Commentary
Public/non profit Ribavirin+Lopinavir+Ritonavir+Interferon alpha Ribavarin+Interferon alpha RCT Patients with confirmed COVID-19 (moderate) admitted to a single center in China N=101
Some concerns
Details

Full description

Lopinavir+Ritonavir+Interferon alpha Ribavarin+Interferon alpha
Ribavirin+Lopinavir+Ritonavir+Interferon alpha Lopinavir+Ritonavir+Interferon alpha
NCT04276688
Hung IF-N, Lancet, 2020
Full text
Commentary
Commentary
Public/non profit LPV/r+RBV+IFN beta1 Lopinavir-Ritonavir RCT Patients with confirmed COVID-19 (unclear severity) admitted to six centers in Hong-Kong N=127
Some concerns
Details

Full description

NCT04412291, EudraCT 2020-001748-24
IMMCOVA, Unpublished, 2021
Public/non profit Standard care Tocilizumab RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a multiple centerd in Sweden N=49
Low
Details

Full description

NCT04434248
Ivashchenko AA, Clin Infect Dis, 2020
Full text
Commentary
Mixed Favipiravir 1800/800mg Favipiravir 1600/600mg RCT Patients with confirmed COVID-19 (moderate) admitted to 6 centers in Russia N=60
Some concerns
Details

Full description

Favipiravir 1600/600mg Standard care
Favipiravir 1800/800mg Standard care
NCT04331899
Jagannathan P, Nature, 2021
Full text
Commentary
Commentary
Mixed Placebo Peginterferon Lambda-1a RCT Outpatients with confirmed COVID-19 (asymptomatic/symptomatic, mild) treated at a single center in the USA N=120
Some concerns
Details

Full description

IRCT20151227025726N17
Jamaati H, Eur J Pharmacol, 2021
Full text
Commentary
Public/non profit Dexamethasone Standard care RCT Patients with confirmed COVID-19 (severe) admitted to a single center in Iran N=50
Some concerns
Details

Full description

IRCT20200411047025N1
JamaliMoghadamSiahkali S, Eur J Med Res, 2021
Full text
Commentary
Public/non profit Vitamin C Standard care RCT Patients with suspected or confirmed COVID-19 (severe) admitted to a single center in Iran N=60 N/A

Full description

NCT04354428
Johnston C, 2021
Full text
Commentary
Commentary
Commentary
Public/non profit Hydroxychloroquine+Azithromycin Vitamin C+Placebo RCT Outpatients with confirmed COVID-19 (asymptomatic-mild) treated by 5 centers in the USA N=231
Some concerns
Details

Full description

Hydroxychloroquine+Azithromycin Hydroxychloroquine+Placebo
Hydroxychloroquine+Placebo Vitamin C+Placebo
IRCT20210214050350N1
Kalantari S, J Med Virol, 2021
Full text
Commentary
Public/non profit Atazanavir+Ritonavir+Dolutegravir+Hydroxychloroquine Hydroxychloroquine+Lopinavir+Ritonavir RCT Patients with confirmed COVID-19 (unclear severity) admitted to a single center in Iran N=* N/A

Full description

NCT04401579
Kalil AC, N Engl J Med, 2020
Full text
Commentary
Public/non profit Baricitinib+Remdesivir Placebo+Remdesivir RCT Patients with confirmed COVID-19 (mild-critical) admitted to 67 centers in Denmark, Japan, Mexico, Singapore, South Korea, Spain, UK, USA. N=1033
Low
Details

Full description

NCT04491994
Kamran S M, Cureus, 2021
Full text
Commentary
Commentary
No specific funding Hydroxychloroquine Standard care RCT Patients with confirmed COVID-19 (mild) admitted to a single center in Pakistan N=540
High
Details

Full description

N/A
Khamis F, Int J Infect Dis, 2020
Full text
Commentary
No specific funding Favipiravir+Interferon beta-1b Hydroxychloroquine RCT Patients with confirmed COVID-19 (moderate-severe) treated at a single center in Oman N=89
Some concerns
Details

Full description

NCT04739410
Khan Chachar AZ, Int J Sci, 2020
Full text
Commentary
No specific funding Ivermectin Standard care RCT Outpatients with confirmed COVID-19 (symptomatic-mild) treated at a single center in Pakistan N=50
High
Details

Full description

NCT04542941
Kirenga B, BMJ Open Respir Res, 2021
Full text
Commentary
Commentary
Public/non profit Convalescent plasma Standard care RCT Patients with confirmed COVID-19 (asymptomatic-severe) admitted to a single center in Uganda. N=136
Some concerns
Details

Full description

N/A
Kishoria N, PIJR, 2020
Full text
Commentary
Not reported/unclear Ivermectin Standard care RCT Patients with confirmed COVID-19 (mild/asymptomatic) admitted to a single center in India. N=32
Some concerns
Details

Full description

DRKS00024520; EudraCT 2020-005544-34
Klussmann J, 2021
Full text
Commentary
Commentary
Private Azelastine 0.02 Placebo RCT Outpatients with confirmed COVID-19 (asymptomatic and mild) treated at a single center in Germany. N=90 N/A

Full description

Azelastine 0.1 Placebo
Azelastine 0.02 Azelastine 0.1
NCT04433910; EudraCT 2020-001310-38
Koerper S, J Clin Invest, 2021
Full text
Full text
Commentary
Commentary
Public/non profit Convalescent plasma Standard care RCT Patients with confirmed COVID-19 (mild-critical) admitted to 13 centers in Germany. N=105
Some concerns
Details

Full description

NCT04355767
Korley F, N Engl J Med, 2021
Full text
rid:crossref.org&rfr_dat=cr_pub%20%200pubmed Commentary
Public/non profit Convalescent plasma Placebo RCT Outpatients and patients with confirmed COVID-19 (symptomatic, mild to moderate) treated at or admitted to 48 centers in the USA. N=511
Some concerns
Details

Full description

NCT04350593
Kosiborod M, Lancet Diabetes Endo, 2021
Full text
00180-7/fulltext Commentary
Private Dapagliflozin Placebo RCT Patients with suspected or confirmed COVID-19 (moderate-severe) admitted to 95 hospitals in Argentina, Brazil, Canada, India, Mexico, UK, USA. N=1250
Low
Details

Full description

NCT04412018
Kosmopoulos A, iScience, 2021
Full text
Commentary
Commentary
Private Icosapent ethyl Standard care RCT Outpatients with confirmed COVID-19 (mild ambulatory) treated at a single center in Canada. N=100
Some concerns
Details

Full description

NCT04381884
Krolewiecki A, EClinicalMedicine, 2021
Full text
Full text
Commentary
Commentary
Mixed Ivermectin Standard care RCT Patients with confirmed COVID-19 (mild-moderate) admitted to 4 centers in Argentina N=45
Some concerns
Details

Full description

CTRI/2020/05/024959
Kumar S, Exp Opin Biol Ther, 2021
Full text
Commentary
Commentary
Private Itolizumab Standard care RCT Patients with confirmed COVID-19 (severe) admitted to 4 centers in India N=32
Some concerns
Details

Full description

N/A
Kumari P, Cureus, 2020
Full text
Commentary
Commentary
Not reported/unclear Vitamin C Standard care RCT Patients with COVID-19 (severe) admitted to a single center in Pakistan N=150 N/A

Full description

NCT04680949; EudraCT 2020-005828-11
Kyriazopoulou E, medRxiv, 2021
Full text
Commentary
Commentary
Mixed Anakinra Placebo RCT Patients with confirmed COVID-19 (mild-severe) admitted to 37 centers in Greece and Italy N=606
Some concerns
Details

Full description

NCT04364022; SNCTP 000003732
Labhardt N, COPEP, 2021
Full text
Commentary
Public/nonprofit Lopinavir-Ritonavir Standard care RCT Asymptomatic individuals ?16 years close contacts with a person with a confirmed SARS-CoV-2 infection N=321
Some concerns
Details

Full description

NCT04355728
Lanzoni G, Stem Cells Transl Me, 2021
Full text
Full text
Commentary
Commentary
Mixed Placebo Umbilical cord mesenchymal stem cell infusion RCT Patients with confirmed COVID-19 (severe-critical) admitted to a single center in USA N=24
Some concerns
Details

Full description

CTRI/2020/10/028423
Lattman E, medRxiv, 2021
Full text
Commentary
Commentary
Private PNB001 Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 2 centers in India. N=40
Some concerns
Details

Full description

NCT02735707, NCT04505774, NCT04359277, NCT04372589
Lawler PR, N Engl J Med, 2021
Full text
Full text
Commentary
Mixed Therapeutic Heparin Prophylactic anticoagulant RCT Patients with confirmed COVID-19 (mild-severe) admitted to 121 centers in Australia, Brazil, Canada, Mexico, Nepal, Netherlands, Spain, UK, USA. N=2244
Some concerns
Details

Full description

RBR-949z6v
Lemos ACB, Thromb Res, 2020
Full text
Commentary
No specific funding Therapeutic enoxaparin Prophylactic anticoagulant RCT Patients with confirmed COVID-19 (critical) admitted to a single center in Brazil N=20
Some concerns
Details

Full description

NCT04342663
Lenze E, JAMA, 2020
Full text
Commentary
Commentary
Mixed Fluvoxamine Placebo RCT Outpatients with confirmed COVID-19 (ambulatory, mild) treated at home in USA N=181
Low
Details

Full description

NCT04327388; EudraCT2020-001162-12; U1111-1249-602
Lescure FX, 2021
Full text
Commentary
Commentary
Private Sarilumab 400mg Placebo RCT Patients with confirmed COVID-19 (moderate-critical) admitted to 45 centers in Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia, and Spain. N=420
Some concerns
Details

Full description

Sarilumab 200mg Placebo
Sarilumab 400mg Sarilumab 200mg
ChiCTR2000029638
Li C, Ann. Med, 2021
Full text
Commentary
Commentary
Mixed Recombinant super-compound interferon Interferon alpha RCT Patients with COVID-19 (moderate-severe) admitted to 5 centers in China N=96
Some concerns
Details

Full description

ChiCTR2000029757
Li L, JAMA, 2020
Full text
Commentary
Commentary
Public/non profit Convalescent plasma Standard care RCT Patients with COVID-19 (severe to critical) admitted to 7 centers in China N=103
Some concerns
Details

Full description

NCT04273763
Li T, Clin Transl Sci , 2020
Full text
Commentary
Public/non profit Bromhexine Standard care RCT Patients with confirmed or suspected COVID-19 (mild-moderate) admitted to a single center in China N=18
Some concerns
Details

Full description

NCT04479163
Libster R, N Engl J Med, 2021
Full text
Commentary
Public/non profit Convalescent plasma Placebo RCT Patients with confirmed COVID-19 (mild) admitted to multiple centers in Argentina N=160
Some concerns
Details

Full description

EudraCT 2020-001243-1
Liesenborghs L, SSRN, 2020
Full text
Commentary
Commentary
Public/non profit Itraconazole Standard care RCT Patients with confirmed or suspected COVID-19 (unclear severity) admitted to a single center in Belgium N=*
Some concerns
Details

Full description

ChiCTR2000030016
Lin YR, J Aerosol Med Pulm Drug Deliv, 2021
Full text
Commentary
Public/non profit Mycobacterium vaccae Standard care RCT Patients with confirmed COVID-19 (moderate) admitted to a single center in China. N=31
Some concerns
Details

Full description

NCT04397562
Lomakin N V, Inflamm Res, 2021
Full text
Commentary
Private Levilimab Placebo RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 12 centers in Russia N=206
Some concerns
Details

Full description

NCT04494984
Lopardo G, EClinicalMedicine, 2021
Full text
Commentary
Commentary
Mixed INM005 Placebo RCT Patients with confirmed (RT-PCR) COVID-19 (mild-severe) pneumonia admitted to 19 centers in Argentina N=245
Some concerns
Details

Full description

RBR-8jyhxh
Lopes MIF, RMD Open, 2021
Full text
Commentary
Public/non profit Colchicine Placebo RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Brazil N=75
Some concerns
Details

Full description

NCT04364893
Lopes RD, JAMA, 2021
Full text
Commentary
Not reported/unclear Discontinue ARB/ACEI Continue ARB/ACEI RCT Patients with suspected COVID-19 (unclear severity) at 29 centers in Brazil N=740
Low
Details

Full description

NCT04394377
Lopes RD, Lancet , 2021
Full text
Commentary
Commentary
Mixed Therapeutic anticoagulant Prophylactic anticoagulant RCT Patients with confirmed COVID-19 (mild-critical) admitted to 31 centers in Brazil N=615
Some concerns
Details

Full description

NCT04405843
Lopez-Medina E, JAMA, 2021
Full text
Commentary
Commentary
Mixed Ivermectin Placebo RCT Outpatients with confirmed COVID-19 (mild) treated by a single center in Colombia N=476
Some concerns
Details

Full description

ChiCTR2000029544
Lou Y, 2020
Full text
Commentary
Public/non profit Favipiravir Standard care RCT Patients with confirmed COVID-19 (unclear severity) admitted to a single center in China N=30
Some concerns
Details

Full description

Baloxavir marboxil Standard care
Favipiravir Baloxavir marboxil
NCT04501978
Lundgren J, medRxiv, 2021
Full text
Full text
Commentary
Mixed Bamlanivimab (LY-CoV555) Placebo RCT Patients with confirmed COVID-19 (mild-severe) admitted to 31 centers in Denmark, Singapore and USA N=326
Some concerns
Details

Full description

NCT04316377
Lyngbakken MN, Nature, 2020
Full text
Commentary
Public/non profit Hydroxychloroquine Standard care RCT Patients with confirmed COVID-19 (mild-severe) admitted to a single center in Norway N=53
High
Details

Full description

N/A
Mahajan L, Indian J Anaesth, 2021
Full text
Commentary
No specific funding Remdesivir Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in India. N=82
High
Details

Full description

NCT04523831
Mahmud R, J Int Med Res, 2021
Full text
Commentary
No specific funding Ivermectin+Doxycycline Placebo RCT Outpatients and inpatients with confirmed COVID-19 (ambulatory-mild-moderate) admitted to a single center in Bangladesh N=400
Some concerns
Details

Full description

N/A
Maldonado V, INT IMMUNOPHARMACOL, 2020
Full text
Commentary
No specific funding Pentoxifylline Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Mexico N=54 N/A

Full description

RBR-5s2mqg
Mansour E, medRxiv, 2020
Full text
Commentary
Public/non profit Icatibant Standard care RCT Patients with COVID-19 (severe) admitted to a single center in Brazil N=30
Some concerns
Details

Full description

C1 Esterase/Kallikrein Inhibitor Standard care
Icatibant C1 Esterase/Kallikrein Inhibitor
NCT04421027
Marconi V, Lancet Respir Med, 2021
Full text
Full text
Full text
Commentary
Commentary
Private Baricitinib Placebo RCT Patients with confirmed COVID-19 (mild-moderate-severe) admitted to 101 centers in Argentina, Brazil, Germany, India, Italy, Japan, Mexico, Russia, South Korea, Spain, UK, USA N=1525
Some concerns
Details

Full description

NCT04341584
Mariette X, Lancet Respir Med, 2021
Full text
Commentary
Public/non profit Anakinra Standard care RCT Patients with COVID-19 (moderate) admitted to 16 centers in France. N=116
Some concerns
Details

Full description

NCT04790786
McCreary E, OPTIMISE-C19, 2021
Full text
Commentary
Commentary
Public/non profit LY-CoV555 Casirivimab+Imdevimab (REGN-COV2) RCT Outpatients with confirmed COVID-19 (mild) treated at multiple ED or outpatient infusion centers or at home in the USA. N=1935
Some concerns
Details

Full description

LY-CoV555+LY-CoV016 Casirivimab+Imdevimab (REGN-COV2)
LY-CoV555 LY-CoV555+LY-CoV016
NCT04468646
Mehboob R, medRxiv, 2020
Full text
Commentary
No specific funding Aprepitant+Dexamethasone Dexamethasone RCT Patients with confirmed COVID-19 (mild-critical) admitted to a single center in Pakistan N=41
Some concerns
Details

Full description

NCT04345614
Miller J, Crit Care, 2020
Full text
Commentary
Private Auxora Standard care RCT Patients with confirmed COVID-19 (moderate) admitted to 3 centers in USA N=26
Some concerns
Details

Full description

NCT04304053
Mitja O, Clin Infect Dis, 2020
Full text
Commentary
Mixed Hydroxychloroquine Standard care RCT Outpatients with COVID-19 (mild) in an ambulatory setting in Spain N=353
Some concerns
Details

Full description

IRCT20200624047908N1
Mobarak S, SSRN, 2021
Full text
Commentary
Commentary
Public/non profit Sofosbuvir-Daclatasvir Placebo RCT Patients with suspected or confirmed COVID-19 (moderate-severe) admitted to 19 centers in Iran N=1083
Some concerns
Details

Full description

CTRI/2020/06/026001
Mohan A, 2021
Full text
Commentary
Mixed Ivermectin 12 mg Placebo RCT Patients with confirmed COVID-19 (mild-moderate) admitted to a single center in India N=152
Some concerns
Details

Full description

Ivermectin 24 mg Placebo
Ivermectin 12 mg Ivermectin 24 mg
ISRCTN16806663
Moni M, medRxiv, 2021
Full text
Commentary
Commentary
Public/non profit Inhaled Nitric Oxide Standard care RCT Patients with confirmed COVID-19 (severe) admitted to a single center in India. N=29
High
Details

Full description

NCT04385095 ; EudraCT 2020-001023-14
Monk PD, Lancet Respir Med, 2020
Full text
Commentary
Commentary
Private Nebulised interferon beta-1a Placebo RCT Patients with confirmed COVID-19 (mild-severe) admitted to nine centers in the UK N=101
Some concerns
Details

Full description

*
Moreira TG, 2021
Full text
Commentary
Commentary
Private Foralumab Standard care RCT Outpatients with confirmed COVID-19 (mild) treated at a single center in Brazil. N=39
High
Details

Full description

Foralumab+Dexamethasone Standard care
Foralumab Foralumab+Dexamethasone
NCT04509973
Munch M, medRxiv, 2021
Full text
Commentary
Commentary
Mixed Dexamethasone 12mg Dexamethasone 6mg RCT Patients with confirmed COVID-19 (severe/critical) admitted to 26 centers in Denmark (11), India (12), Sweden (2) and Switzerland (1). N=982
Some concerns
Details

Full description

NCT04348305
Munch MW, Acta Anaesthesiol Sc, 2021
Full text
Commentary
Mixed Hydrocortisone Placebo RCT Patients with confirmed COVID-19 (severe/critical) admitted to 12 centers in Denmark N=30
Low
Details

Full description

NCT04449718
Murai IH, Jama, 2021
Full text
Commentary
Commentary
Public/non profit Placebo Cholecalciferol RCT Patients with COVID-19 (mild-severe) admitted to 2 centres in Brazil N=240
Some concerns
Details

Full description

NCT04334148
Naggie S
Full text
Commentary
Commentary
Public/nonprofit Hydroxychloroquine Placebo RCT NR N=1360
Some concerns
Details

Full description

IRCT20151113025025N3
Najmeddin F, Am J Hypertens, 2021
Full text
Commentary
Public/non profit Continue ARB/ACEI Discontinue ARB/ACEI RCT Patients with confirmed COVID-19 (mild-critical) admitted to 3 centers in Iran. N=66
Some concerns
Details

Full description

IRCT20200408046987N1
Niaee MS, Asian Pac J Trop Med, 2021
Full text
Commentary
Commentary
Mixed Ivermectin Once-off Standard care RCT Patients with CT or PCR confirmed COVID-19 (unclear severity) admitted to 5 centers in Iran. N=180
Some concerns
Details

Full description

Ivermectin Once-off Placebo
Ivermectin 3-day LD Standard care
Ivermectin 3-day LD Placebo
Ivermectin 1-day BDS Standard care
Ivermectin 1-day BDS Placebo
Ivermectin 3-day HD Standard care
Ivermectin 3-day HD Placebo
IRCT20180725040596N2
Nojomi M, BMC Infect Dis., 2020
Full text
Commentary
Public/non profit Hydroxychloroquine+Umifenovir Hydroxychloroquine+Lopinavir-Ritonavir RCT Patients with COVID-19 (moderate-severe) admitted to a single center in Iran N=100
Some concerns
Details

Full description

IRCT20180802040678N4
Nouri-Vaskeh M, Int J Clin Pract, 2021
Full text
Commentary
Public/non profit Losartan Amlodipine RCT Patients with confirmed COVID-19 (mild-moderate-severe-critical) admitted to a single center in Iran N=82
Some concerns
Details

Full description

IRCT20100228003449N29
Nourian A, Acta Biomed, 2020
Full text
Commentary
Mixed Sofosbuvir-ledipasvir Standard care RCT Patients with suspected or confirmed COVID-19 (mild-severe) admitted to a single center in Iran N=90
Some concerns
Details

Full description

NCT04452318
O Brien M P, medRxiv, 2021
Full text
Full text
Commentary
Commentary
Mixed Casirivimab+Imdevimab (REGN-COV2) Placebo RCT Outpatients with confirmed COVID-19 (mild, asymptomatic) treated at 112 centers in the Moldova, Romania, and USA. N=314
Some concerns
Details

Full description

NCT04359810
O Donnell M, J Clin Invest, 2021
Full text
Commentary
Commentary
Not reported/unclear Convalescent plasma Control plasma RCT Patients with confirmed COVID-19 (mild-critical) admitted to 5 centers in Brazil and USA N=223
Low
Details

Full description

NCT04646109
Okumus N, BMC Infectious Disea, 2021
Full text
Commentary
Commentary
Public/non profit Ivermectin Standard care RCT Patients with confirmed COVID-19 (severe) admitted to four centers in Turkey N=66
High
Details

Full description

NCT04332107
Oldenburg CE, JAMA, 2021
Full text
Commentary
Commentary
Mixed Azithromycin Placebo RCT Outpatients with confirmed COVID-19 (mild, asymptomatic and symptomatic) enrolled in the community in the USA. N=263
Some concerns
Details

Full description

NCT04349592
Omrani A, Q-PROTECT, 2020
Full text
Commentary
Public/non profit Hydroxychloroquine+Azithromycin Placebo RCT Outpatients with confirmed COVID-19 (mild) treated by 2 centers in Qatar N=456
Some concerns
Details

Full description

Hydroxychloroquine+Azithromycin Hydroxychloroquine
Hydroxychloroquine Placebo
CTRI/2020/05/025013
Padmanabhan U, medRixv, 2020
Full text
Commentary
Commentary
Mixed Bacille Calmette-Guérin Placebo RCT “Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in India” N=60
Some concerns
Details

Full description

ISRCTN83971151; NCT04315948
Pan H, N Engl J Med, 2020
Full text
Full text
Commentary
Mixed Remdesivir Standard care RCT Patients with COVID-19 (mild-critical) admitted to 405 centers in 30 countries N=5475
Low
Details

Full description

ISRCTN83971151; NCT04315948
Pan H, N Engl J Med, 2020
Full text
Full text
Commentary
Mixed Interferon beta-1a Standard care RCT Patients with COVID-19 (mild-critical) admitted to 405 centers in 30 countries. N=4127
Low
Details

Full description

ISRCTN83971151; NCT04315948
Pan H, N Engl J Med, 2020
Full text
Full text
Commentary
Mixed Lopinavir-Ritonavir Standard care RCT Patients with COVID-19 (mild-critical) admitted to 405 centers in 30 countries. N=2791
Low
Details

Full description

ISRCTN83971151; NCT04315948
Pan H, N Engl J Med, 2020
Full text
Full text
Commentary
Mixed Hydroxychloroquine Standard care RCT Patients with COVID-19 (mild-critical) admitted to 405 centers in 30 countries N=1863
Low
Details

Full description

CTRI/2020/06/026087
Pandit A, Int J Infect Dis, 2021
Full text
Commentary
Private Pegylated Interferon alpha-2b Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 6 centers in India N=40
Some concerns
Details

Full description

NCT04685512; EuraCT 2020-001867-94
Parientia JJ, EClinicalMedicine, 2021
Full text
Commentary
Public/non profit Tenofovir+Emtricitabine Standard care RCT Outpatients with confirmed COVID-19 (mild, symptomatic) treated by 2 centers in France N=60
Some concerns
Details

Full description

NCT04350320 ; EUDRACT 2020-001511-2
Pascual-Figal DA, Int J Gen Med, 2021
Full text
Commentary
Public/non profit Colchicine Standard care RCT Patients with confirmed COVID-19 (mild-moderate) admitted to hospital in Spain. N=103
Some concerns
Details

Full description

NCT04376684
Patel J, medRxiv, 2021
Full text
Commentary
Commentary
Private Otilimab Placebo RCT Patients with confirmed COVID-19 (severe-critical) admitted to 108 centers in 17 countries N=806
Some concerns
Details

Full description

ACTRN12620000454976
Patel O, J Med Virol, 2021
Full text
Commentary
Public/non profit Zinc Placebo RCT Patients with confirmed COVID-19 (mild-critical) admitted to a single center in Australia N=33
Low
Details

Full description

NCT04360824
Perepu U, J Thromb Haemost, 2021
Full text
Full text
Commentary
Public/non profit Intermediate-Dose Enoxaparin Standard-Dose prophylactic anticoagulation RCT Patients with confirmed COVID-19 (severe-critical) admitted to 3 centers in the USA. N=176
Low
Details

Full description

NCT04412057
Perlin DS , medRxiv, 2021
Full text
Commentary
Commentary
Private CERC-002 Placebo RCT Patients with confirmed COVID-19 (severe) admitted to 11 centers in the USA N=83 N/A

Full description

NCT04348305
Perner A, Unpublished, 2020
Mixed Hydrocortisone Placebo RCT Patients with confirmed COVID-19 (severe-critical) admitted to 19 centers in Denmark. N=29
Low
Details

Full description

N/A
Podder C, IMC J Med Sci, 2020
Full text
No specific funding Ivermectin Standard care RCT Outpatients with confirmed COVID-19 (mild-moderate) treated at a single center in Bangladesh N=*

Details

Full description

NCT04431466
Pott-Junior H, 2021
Full text
Commentary
No specific funding Ivermectin 100 mcg/kg Standard care RCT Patients with RT-PCR confirmed COVID-19 (symptomatic mild) admitted to a single center in Brazil. N=32
Some concerns
Details

Full description

Ivermectin 100 mcg/kg Ivermectin 200 mcg/kg
Ivermectin 100 mcg/kg Ivermectin 400 mcg/kg
Ivermectin 200 mcg/kg Standard care
Ivermectin 200 mcg/kg Ivermectin 400 mcg/kg
Ivermectin 400 mcg/kg Standard care
IRCT20200310046736N1
Pouladzadeh M, Intern Emerg Med, 2021
Full text
Commentary
Public/non profit Convalescent plasma Standard care RCT Patients with confirmed COVID-19 (severe-critical) admitted to a single center in Iran N=62
Some concerns
Details

Full description

NCT04343729
Prado Jeronimo CM, Clin Infect Dis, 2020
Full text
Commentary
Public/non profit Methylprednisolone Placebo RCT Patients with COVID-19 (moderate-critical) admitted to a single center in Brazil N=416
High
Details

Full description

INA-TX6YYSS
Purwati, 2021
Full text
Commentary
Public/non profit Lopinavir-Ritonavir(Low dose)+Azithromycin Azithromycin RCT NR N=759 N/A

Full description

Lopinavir-Ritonavir(Low dose)+Doxycycline Azithromycin
Hydroxychloroquine+Azithromycin Azithromycin
Lopinavir-Ritonavir+Azithromycin Azithromycin
Lopinavir-Ritonavir+Doxycycline Azithromycin
NCT04311177
Puskarich M, EClinicalMedicine, 2021
Full text
Commentary
Public/non profit Losartan Placebo RCT Outpatients with confirmed COVID-19 (mild) treated at 3 centers in the USA N=117
Low
Details

Full description

NCT04312009
Puskarich M, medRxiv, 2021
Full text
Commentary
Commentary
Public/non profit Losartan Placebo RCT Patients with confirmed COVID-19 (mild - critical) admitted to 13 centers in the US. N=205
Some concerns
Details

Full description

IRCT20100228003449N27
Rahmani H, Int Immunopharmacol, 2020
Full text
Commentary
No specific funding Interferon beta-1b Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Iran N=80
Some concerns
Details

Full description

NCT04416399
Ramakrishnan S, Lancet Respir Med, 2021
Full text
Commentary
Commentary
Mixed Budesonide Standard care RCT Outpatients with suspected or confirmed COVID-19 (mild) treated by a single center in the UK N=146 N/A

Full description

CTRI/2020/06/026222
Raman RS, J Infect Dis, 2021
Full text
Commentary
Private Intravenous Immunoglobulin Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to four centers in India N=100
Some concerns
Details

Full description

IRCT20200204046369N1
Ranjbar K, BMC Infect Dis, 2021
Full text
Commentary
Commentary
No specific funding Methylprednisolone Dexamethasone RCT Patients with confirmed COVID-19 (severe-critical) admitted to a single center in Iran N=93
Some concerns
Details

Full description

*
Rashad A, 2021
Full text
Commentary
Commentary
Not reported/unclear Azithromycin Standard care RCT Patients with confirmed COVID-19 (mild outpatients) treated at a single center in Egypt N=305 N/A

Full description

Azithromycin Clarithromycin
Clarithromycin Standard care
NCT04519385
Rashad A, Scientific Reports, 2021
Full text
Commentary
Commentary
Not reported/unclear Tocilizumab Dexamethasone RCT Patients with confirmed COVID-19 (severe-critical) admitted to a single center in Egypt N=149
High
Details

Full description

N/A
Rasheed A, Le Infezioni in Medi, 2020
Full text
Public/non profit Convalescent plasma Standard care RCT Patients with COVID-19 (severe) admitted to 3 centers in Iraq. N=49 N/A

Full description

NCT04459247
Rastogi A, Postgrad Med J, 2020
Full text
Commentary
Commentary
No specific funding Cholecalciferol Placebo RCT Patients with confirmed COVID-19 (symptomatic or asymptomatic mild) admitted to a single center in India N=40 N/A

Full description

CTRI/2021/05/033544
Ravichandran R, medRxiv, 2021
Full text
Commentary
Commentary
Not reported/unclear Indomethacin Standard care RCT Patients with confirmed COVID-19 (mild-moderate) admitted to a single center in India. N=210
Some concerns
Details

Full description

CTRI/2020/08/027225
Ravikirti R, J Pharm Pharm Sci, 2021
Full text
Full text
Commentary
Commentary
Commentary
Mixed Ivermectin Placebo RCT Patients with COVID-19 (mild-severe) admitted to a single center in India N=115
High
Details

Full description

CTRI/2020/05/025209
Ray Y, medRxiv, 2020
Full text
Commentary
Commentary
Public/non profit Convalescent plasma Standard care RCT Patients with confirmed COVID-19 (severe) admitted to a single center in India N=80
High
Details

Full description

NCT04420247
Rea-Neto A, Scientific Reports, 2021
Full text
Commentary
Not reported/unclear Chloroquine/Hydroxychloroquine Standard care RCT Patients with confirmed COVID-19 (moderate-severe-critical) admitted to 6 centers in Brazil N=142
Some concerns
Details

Full description

NCT04727424
Reis G, medRxiv, 2021
Full text
Commentary
Commentary
Public/non profit Fluvoxamine Placebo RCT Outpatients with confirmed COVID-19 (mild, symptomatic) treated by 11 centers in Brazil N=1472
Low
Details

Full description

NCT04403100
Reis G, TOGETHER, 2021
Full text
Commentary
Commentary
Public/non profit Lopinavir-Ritonavir Placebo RCT Outpatients with confirmed COVID-19 (mild) treated at local public health facilities in 10 cities in Brazil N=685
Some concerns
Details

Full description

Lopinavir-Ritonavir Hydroxychloroquine
Hydroxychloroquine Placebo
NCT04409262
REMDACTA, Unpublished, 2021
Private Placebo Tocilizumab RCT Patients with confirmed COVID-19 (severe-critical) admitted to a multiple centers in Spain, USA, Brazil and Russia. N=640
Some concerns
Details

Full description

ChiCTR2000029853
Ren Z, Adv Sci, 2020
Full text
Commentary
Mixed Azvudine Standard care RCT Patients with COVID-19 (mild-moderate) admitted to a single center in China N=20
Some concerns
Details

Full description

RBR-5vpyh4
Resende GG, medRxiv, 2021
Full text
Commentary
Commentary
Mixed Secukinumab Standard care RCT Patients with confirmed COVID-19 (unclear severity) admitted to a single center in Brazil N=50
Some concerns
Details

Full description

NCT04552483
Rocco PRM, Eur Respir J, 2020
Full text
Commentary
Mixed Nitazoxanide Placebo RCT Outpatients with confirmed COVID-19 (mild) treated at 7 centers in Brazil N=475
Some concerns
Details

Full description

RBR-95yjmq
Rodrigues C, Int J Antimicrob Agents, 2021
Full text
Commentary
Private Hydroxychloroquine + Azithromycin Placebo RCT Outpatients with confirmed COIVD-19 (symptomatic, mild) treated by a single center in Brazil N=84
Low
Details

Full description

IRCT20190810044500N7
Roostaei A, BMC Infect Dis, 2021
Full text
Commentary
Commentary
Public/non profit Levamisole Placebo RCT Outpatients with COVID-19 (mild) treated at a single center in Iran N=52
Some concerns
Details

Full description

IRCT20200403046926N1
Roozbeh F, J Antimicrob Chemoth, 2020
Full text
Commentary
Public/non profit Sofosbuvir-Daclatasvir Standard care RCT Outpatients with COVID-19 (mild) treated at a single center in Iran N=60 N/A

Full description

NCT04320615
Rosas I, N Engl J Med, 2021
Full text
Commentary
Mixed Tocilizumab Placebo RCT Patients with confirmed COVID-19 (mild-critical) admitted to multiple centers across 9 countries N=452
Low
Details

Full description

NCT04486313
Rossignol JF, medRxiv, 2021
Full text
Commentary
Commentary
Private Nitazoxanide Placebo RCT Outpatients with confirmed or suspected COVID-19 (mild, symptomatic) treated at 36 centers in Puerto Rico and USA. N=*
Some concerns
Details

Full description

Trial NL8504
Rutgers A, SSRN, 2021
Full text
Commentary
Mixed Tocilizumab Standard care RCT Patients with confirmed COVID-19 (moderate-critical) admitted to 11 centers in the Netherlands. N=354
Some concerns
Details

Full description

NCT04501783
Ruzhentsova TA, SSRN, 2020
Full text
Commentary
Commentary
Private Favipiravir Standard care RCT Outpatients and inpatients with confirmed COVID-19 (mild-moderate) treated at 10 centers in Russia N=168
Some concerns
Details

Full description

Saudi Clinical Trial Registry (SCTR): 20061006
Sabico S, Nutrients, 2021
Full text
Commentary
Mixed Vitamin D 5000 IU Vitamin D 1000 IU RCT Patients with confirmed COVID-19 (mild outpatients or hospitalised mild-moderate) admitted or treated by 2 centers in Saudi Arabia N=73
Some concerns
Details

Full description

IRCT20200128046294N2
Sadeghi A, J Antimicrob Chemoth, 2020
Full text
Commentary
Mixed Sofosbuvir-Daclatasvir Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 4 centers in Iran N=70
Some concerns
Details

Full description

NCT04411667
Sakoulas G, Crit Care Expl , 2020
Full text
Commentary
Private Intravenous Immunoglobulin Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 2 centers in USA. N=34
Some concerns
Details

Full description

NCT04372186
Salama C, N Engl J Med, 2020
Full text
Full text
Commentary
Commentary
Private Tocilizumab Placebo RCT Patients with confirmed COVID-19 (mild-severe) admitted to 65 centers in Brazil, Kenya, Mexico, Peru, South Africa, and USA N=388
Some concerns
Details

Full description

IRCT20200418047126N1
Salehzadeh F, Research Square, 2020
Full text
Commentary
Public/non profit Colchicine Placebo RCT Patients with confirmed COVID-19 (unclear severity) admitted to a single center in Iran N=100
Some concerns
Details

Full description

N/A
Sali S, Novelty in Biomedicine, 2021
Full text
Public/non profit Hydroxychloroquine+Sofosbuvir Hydroxychloroquine+Lopinavir-Ritonavir RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Iran N=54
Some concerns
Details

Full description

NCT04530370
Salman OH, Egypt J Anaesth, 2020
Full text
Commentary
Not reported/unclear Convalescent plasma Standard care RCT Patients with confirmed COVID-19 (severe) admitted to a single center in Egypt N=30
Some concerns
Details

Full description

NCT04346355
Salvarani C, JAMA , 2020
Full text
Commentary
Mixed Tocilizumab Standard care RCT Patients with confirmed COVID-19 (severe) admitted to 24 centers in Italy N=126
Some concerns
Details

Full description

ChiCTR2000033627
Samaha A,, Viruses, 2021
Full text
Commentary
No specific funding Ivermectin Standard care RCT Outpatients with confirmed COVID-19 (asymptomatic-mild) recruited through testing centers in Lebanon. N=100
Some concerns
Details

Full description

IRCT20200509047364N2
Samimagham HR, Research Square, 2021
Full text
Commentary
Commentary
Public/non profit Famotidine Standard care RCT Patients with confirmed COVID-19 (unclear severity) admitted to a single center in Iran N=20
Some concerns
Details

Full description

NCT04489446
Santamarina MG, SSRN, 2021
Full text
Commentary
Commentary
No specific funding Sildenafil Placebo RCT Patients with confirmed COVID-19 (mild-severe) admitted to a single center in Chile. N=40 N/A

Full description

NCT04357808
SARCOVID, Unpublished, 2021
Mixed Sarilumab Standard care RCT Patients with confirmed COVID-19 (mild-severe) admitted to a single center in Spain. N=30
Low
Details

Full description

NCT04357860, EU-CTR 2020-001531-27
SARICOR, Unpublished, 2021
Public/non profit Sarilumab Standard care RCT Patients with confirmed COVID-19 (moderate) admitted to 10 centers in Spain N=115
Low
Details

Full description

EU-CTR 2020-002037-15
SARTRE, Unpublished, 2021
Private Sarilumab Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 5 centers in Spain N=140
Low
Details

Full description

IRCT20130812014333N145
Sayad B, J Antimicrob Chemother, 2021
Full text
Commentary
Public/non profit Sofosbuvir/Velpatasvir Standard care RCT Patients with confirmed or suspected COVID-19 (severe) admitted to a single center in Iran. N=80
Some concerns
Details

Full description

NCT04329611
Schwartz I, CMAJ Open, 2021
Full text
Commentary
Mixed Hydroxychloroquine Placebo RCT Outpatients with confirmed COVID-19 (mild, symptomatic) treated in the community by the public health system in Canada N=148
Some concerns
Details

Full description

IRCT20200511047399N1
Sedighiyan M, Authorea, 2021
Full text
Commentary
Public/non profit Hydroxychloroquine+Omega-3 Hydroxychloroquine RCT Patients with COVID-19 (unclear severity) admitted to a single center in Iran N=39 N/A

Full description

IRCT20200415047092N1
Sekhavati E, Int J Antimicrob Age, 2020
Full text
Commentary
Public/non profit Azithromycin Standard care RCT Patients with COVID-19 confirmed (moderate-severe) admitted to a single center in Iran N=111
Some concerns
Details

Full description

NCT04547660
Sekine L, Eur Respir J, 2021
Full text
Commentary
Public/non profit Convalescent plasma Standard care RCT Patients with confirmed COVID-19 (moderate-critical) admitted to a single center in Brazil. N=160
Some concerns
Details

Full description

NCT04332991
Self W, JAMA, 2020
Full text
Commentary
Commentary
Mixed Hydroxychloroquine Placebo RCT Patients with COVID-19 confirmed (mild-critical) admitted to 34 centers in the USA N=479
Some concerns
Details

Full description

NCT04392713
Shah Bukhari K H, medRxiv, 2021
Full text
Commentary
Commentary
Not reported/unclear Ivermectin Standard care RCT Patients with confirmed COVID-19 (mild) admitted to a single center in Pakistan N=100
High
Details

Full description

IRCT20111224008507N3
Shahbaznejad L, Clin Ther, 2021
Full text
Commentary
No specific funding Ivermectin Standard care RCT Patients with suspected or confirmed COVID-19 (moderate-critical) admitted to 2 centers in Iran. N=73
Some concerns
Details

Full description

NCT04288102
Shi L, Signal Transduction , 2021
Full text
Commentary
Public/non profit Human umbilical cord mesenchymal stem cell infusion Placebo RCT Patients with confirmed COVID-19 (severe) admitted to two centers in China N=101
Some concerns
Details

Full description

JapicCTI-205238
Shinkai M, Infect Dis Ther, 2021
Full text
Commentary
Private Favipiravir Placebo RCT Patients with confirmed COVID-19 (mild/moderate) admitted to 39 centers in Japan. N=156
Some concerns
Details

Full description

NCT04362085; NCT04444700
Sholzberg M, medRxiv, 2021
Full text
Commentary
Commentary
Public/non profit Therapeutic Heparin Prophylactic Heparin RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a 28 centers in Brazil, Canada, Ireland, Saudi Arabia, UAE, USA. N=465
Some concerns
Details

Full description

ChiCTR2000031494
Shu L, Stem Cell Res Ther, 2020
Full text
Commentary
Public/non profit Human umbilical cord mesenchymal stem cell infusion Standard care RCT Patients with COVID-19 (severe) admitted to a single center China N=41
Some concerns
Details

Full description

IRCT20200504047298N3
Siami Z, Int J Infect Dis, 2021
Full text
Commentary
Public/non profit Ammonium chloride Placebo RCT Outpatients and inpatients with suspected or confirmed COVID-19 admitted to or treated by a single center in Iran N=120
High
Details

Full description

NCT04512027; CTRI/2020/09/027833
Sigamani A, J Vaccines Vaccin, 2020
Full text
Commentary
Private Prolectin-M Standard care RCT Patients with confirmed COVID-19 (mild) admitted to a single center in India N=10
Some concerns
Details

Full description

NCT04463264
Silva M, medRxiv, 2021
Full text
Commentary
Commentary
Private Nitazoxanide Placebo RCT Outpatients and inpatients with confirmed COVID-19 (asymptomatic or symptomatic-mild) treated by or admitted to two centers in Argentina N=46
High
Details

Full description

NCT04383535
Simonovich VA, N Engl J Med, 2020
Full text
Commentary
Mixed Convalescent plasma Placebo RCT Patients with confirmed COVID-19 (severe) admitted to 12 centers in Argentina N=334
Some concerns
Details

Full description

CTRI/2020/06/025575
Singh B(2), medRxiv, 2021
Full text
Commentary
Commentary
No specific funding Hydroxychloroquine+Ribavirin Standard care RCT Patients with confirmed COVID-19 (mild-moderate) admitted to a single center in India. N=40
Some concerns
Details

Full description

CTRI/2020/06/025575
Singh B, 2021
Full text
Commentary
Commentary
No specific funding HCQ+RBV Standard care RCT Patients with confirmed COVID-19 (severe-critical) admitted to a single center in India. N=71
Some concerns
Details

Full description

LPV/r+RBV Standard care
HCQ+RBV LPV/r+RBV
NCT04402866; EudraCT 2020-001807-18
Singh D, 2021
Full text
Commentary
Commentary
Private TD-0903 1 mg Placebo RCT Patients with confirmed COVID-19 (moderate) admitted to centers in Moldova, UK and Ukraine. N=25
Some concerns
Details

Full description

TD-0903 1 mg TD-0903 3 mg
TD-0903 1 mg TD-0903 10 mg
TD-0903 3 mg Placebo
TD-0903 3 mg TD-0903 10 mg
TD-0903 10 mg Placebo
NCT04322396, EudraCT 2020-001198-55
Sivapalan P, Eur Respir J, 2021
Full text
Commentary
Mixed Hydroxychloroquine + Azithromycin Placebo RCT Patients with confirmed COVID-19 (mild-severe) admitted to 6 centers in Denmark N=117
Low
Details

Full description

NCT04315298
Sivapalasingam S (1), 2021
Full text
Commentary
Commentary
Private Sarilumab 400mg Placebo RCT Patients with confirmed COVID-19 (moderate-critical) admitted to 56 centers in the USA N=457
Some concerns
Details

Full description

Sarilumab 200mg Placebo
Sarilumab 400mg Sarilumab 200mg
NCT04315298
Sivapalasingam S (2), 2021
Full text
Commentary
Commentary
Private Sarilumab 400mg Placebo RCT Patients with confirmed COVID-19 (moderate-severe-critical) admitted to 56 centers in the USA N=1330
Some concerns
Details

Full description

Sarilumab 200mg Placebo
Sarilumab 400mg Sarilumab 200mg
NCT04308668
Skipper CP, Ann Intern Med, 2020
Full text
Commentary
Private Hydroxychloroquine Placebo RCT Outpatients with suspected or confirmed COVID-19 (symptomatic, mild) with high-risk exposure within 4 days of symptom onset N=491
Some concerns
Details

Full description

NCT04715295
Sobngwi E, medRxiv, 2021
Full text
Commentary
Commentary
Public/non profit Doxycycline Hydroxychloroquine + Azithromycin RCT Outpatients with confirmed COVID-19 (asymptomatic and mild) treated at a single center in Cameroon. N=194
Some concerns
Details

Full description

CTRI/2020/05/025369
Soin AS, Lancet Respir Med, 2021
Full text
Commentary
Mixed Tocilizumab Standard care RCT Patients with confirmed COVID-19 (moderate-critical) admitted to 12 centers in India N=180
Some concerns
Details

Full description

NCT04341038; EudraCT 2020-001445-39
Solanich X, Front Med, 2021
Full text
Commentary
Commentary
Public/non profit Methylprednisolone pulse+Tacrolimus Standard care RCT Patients with confirmed COVID-19 (severe) admitted to a single center in Spain N=55
Some concerns
Details

Full description

IRCT20200318046812N1
Solaymani-Dodaran M, Int Immunopharmacol, 2021
Full text
Commentary
Public/non profit Favipiravir Lopinavir-Ritonavir RCT Patients with suspected or confirmed COVID-19 (severe) admitted to 20 centers in Iran N=424
Some concerns
Details

Full description

NCT04330586
Song JY, J Clin Med, 2021
Full text
Commentary
Mixed Ciclesonide Standard care RCT Patients with confirmed COVID-19 (mild-moderate) admitted to 6 centers in South Korea. N=*
High
Details

Full description

NCT04292730
Spinner CD, JAMA, 2020
Full text
Commentary
Private Remdesivir 5 days Standard care RCT Patients with COVID-19 (mild-severe) admitted to 105 centers in the USA, Europe and Asia N=596
Some concerns
Details

Full description

Remdesivir 10 days Standard care
Remdesivir 5 days Remdesivir 10 days
NCT04356937
Stone JH, N Engl J Med, 2020
Full text
Commentary
Private Tocilizumab Placebo RCT Patients with COVID-19 (mild-severe) admitted to seven centers in USA N=243
Low
Details

Full description

NCT04579393
Strich JR, Clin Infect Dis, 2021
Full text
Commentary
Commentary
Mixed Fostamatinib Placebo RCT Patients with confirmed COVID-19 (moderate-critical) admitted to 2 centers in USA. N=59
Low
Details

Full description

IRCT20151227025726N20
Tabarsi P, Int Immunopharmacol, 2020
Full text
Commentary
Public/non profit Intravenous Immunoglobulin Standard care RCT Patients with COVID-19 (severe) admitted to a single center in Iran N=84
Some concerns
Details

Full description

IRCT20081027001411N4
Talaschian M, Research Square, 2021
Full text
Commentary
Commentary
Public/non profit Tocilizumab Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Iran N=40
High
Details

Full description

ChiCTR2000029868
Tang W, BMJ, 2020
Full text
Commentary
Commentary
Mixed Hydroxychloroquine Standard care RCT Patients with COVID-19 (mild, moderate and severe) admitted to 16 centers in China N=150
Some concerns
Details

Full description

NCT04273321
Tang X, Respiration, 2021
Full text
Commentary
Public/non profit Methylprednisolone Placebo RCT Patients with confirmed COVID-19 (moderate/severe) admitted to 7 centers in China. N=86
Some concerns
Details

Full description

NCT04322682
Tardif JC, Lancet Respir Med, 2021
Full text
Commentary
Commentary
Mixed Colchicine Placebo RCT Outpatients with suspected or confirmed COVID-19 (mild) at multiple centers in Brazil, Canada, Greece, South Africa, Spain, USA N=*

Details

Full description

NCT04351152
Temesgen Z, medRxiv, 2021
Full text
Commentary
Commentary
Private Lenzilumab Placebo RCT Patients with confirmed COVID-19 (moderate to severe) admitted to 29 centers in Brazil and USA. N=520
Some concerns
Details

Full description

CTRI/2020/04/024729
Thakar A, Indian J Med Res, 2021
Full text
Commentary
Commentary
Public/non profit Chloroquine Standard care RCT Patients with confirmed COVID-19 (asymptomatic-mild) admitted to a single center in India N=60
Some concerns
Details

Full description

NCT04342728
Thomas S, COVID A to Z, 2021
Full text
Commentary
Commentary
Not reported/unclear Vitamin C Standard care RCT Outpatients with confirmed COVID-19 (asymptomatic-mild) treated by multiple centers in the US. N=214
Some concerns
Details

Full description

Vitamin C Zinc
Vitamin C Vitamin C+Zinc
Zinc Vitamin C+Zinc
Zinc Standard care
Vitamin C+Zinc Standard care
NCT04332094, EudraCT 2020-001442-19
TOCOVID, Unpublished, 2021
Public/non profit Standard care Tocilizumab RCT Patients with confirmed COVID-19(mild-moderate) admitted to multiple centers in Spain. N=270
Low
Details

Full description

IRCT20151227025726N24
Tolouian R, J Investig Med, 2021
Full text
Commentary
Commentary
No specific funding Bromhexine hydrochloride Standard care RCT Patients with confirmed COVID-19 pneumonia (symptomatic, unclear severity) admitted to a single center in Iran N=111
High
Details

Full description

NCT04327401
Tomazini BM, JAMA, 2020
Full text
Commentary
Mixed Dexamethasone Standard care RCT Patients with suspected or confirmed COVID-19 (critical) admitted to 41 centers in Brazil N=299
Some concerns
Details

Full description

NCT04452435
Tornling G, SSRN, 2021
Full text
Full text
Commentary
Commentary
Mixed Compound 21 Placebo RCT Patients with confirmed COVID-19 (mild-moderate) admitted to 8 centers in India N=106
Some concerns
Details

Full description

CTRI/2020/05/025114
Udwadia Z, Int J Infect Dis, 2020
Full text
Commentary
Private Favipiravir Standard care RCT Patients with confirmed COVID-19 (mild/moderate) admitted to 7 centers in India N=150
Some concerns
Details

Full description

NCT04369742
Ulrich RJ, Open Forum Infect Di, 2020
Full text
Commentary
Public/non profit Hydroxychloroquine Placebo RCT Patients with confirmed COVID-19 (mild-severe) admitted to 5 centers in USA N=128
Some concerns
Details

Full description

NCT04324073

Unpublished, 2021
Public/non profit Sarilumab Standard care RCT Patients with suspected or confirmed COVID-19 (severe-critical) admitted to multiple centers in France. N=*
Some concerns
Details

Full description

NCT04529525
Vallejos J, BMC Infect Dis, 2021
Full text
Commentary
No specific funding Ivermectin Placebo RCT Outpatients with confirmed COVID-19 (asymptomatic-mild) treated by a single center in Argentina N=501
Low
Details

Full description

NCT04403685
Veiga VC, BMJ, 2021
Full text
Commentary
Commentary
Mixed Tocilizumab Standard care RCT Patients with confirmed COVID-19 (moderate-critical) admitted to 9 centers in Brazil N=129
Some concerns
Details

Full description

NCT04325061
Villar J, Unpublished, 2020
Public/non profit Dexamethasone Standard care RCT Patients with confirmed COVID-19 (critical) admitted 14 centers in Spain N=19
Low
Details

Full description

NCT04333420
Vlaar APJ, Lancet Rheumatol, 2020
Full text
Commentary
Private IFX-1 Standard care RCT Patients with confirmed COVID-19 (moderate-critical) admitted to three centers N=30
Some concerns
Details

Full description

ChiCTR2000029765
Wang D, Front Med, 2021
Full text
Full text
Commentary
Public/non profit Tocilizumab Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 6 centers in China N=65
Some concerns
Details

Full description

ChiCTR2000030058
Wang M, Clin Infect Dis, 2020
Full text
Commentary
Public/non profit Leflunomide + Interferon alpha2a Interferon alpha2a RCT Patients with confirmed COVID-19 (mild) admitted to a single center China N=50
Some concerns
Details

Full description

NCT04257656
Wang Y, Lancet, 2020
Full text
Commentary
Mixed Remdesivir Placebo RCT Patients with confirmed COVID-19 (severe) admitted to 10 centers in China N=237
Some concerns
Details

Full description

NCT04425629
Weinreich D (2), medRxiv, 2021
Full text
Commentary
Commentary
Mixed Casirivimab+Imdevimab (REGN-COV2) 1200mg Placebo RCT Outpatients with confirmed COVID-19 (mild) treated at 82 centers in Mexico and the USA. N=1678
Some concerns
Details

Full description

NCT04425629
Weinreich D, medRxiv, 2021
Full text
Commentary
Commentary
Mixed Casirivimab+Imdevimab (REGN-COV2) 2400mg Placebo RCT Outpatients with confirmed COVID-19 (mild) treated in 82 centers in Mexico and the USA. N=3029
Some concerns
Details

Full description

N/A
Winchester S, J Infect, 2021
Full text
00251-6/fulltext Commentary
Private Nitric Oxide Nasal Spray Placebo RCT Patients with confirmed COVID-19 (mild) isolated and treated at a single center in the UK. N=80
Some concerns
Details

Full description

ChiCTR2000030001
Wu X, Engineering, 2020
Full text
Commentary
Public/non profit Triazavirin Placebo RCT Patients with confirmed COVID-19 (moderate-critical) admitted to 10 centers in China N=52
Some concerns
Details

Full description

IRCT20200328046885N1
Yadollahzadeh M, Research square , 2021
Full text
Commentary
Commentary
Public/non profit Sofosbuvir-Daclatasvir Lopinavir-Ritonavir RCT Patients with CT-scan-confirmed COVID-19 (moderate-severe) admitted to a single center in Iran N=112
High
Details

Full description

DRKS00022203
Yakoot M, SSRN, 2020
Full text
Commentary
Commentary
Private Sofosbuvir-Daclatasvir Standard care RCT Patients with confirmed COVID-19 (mild-severe) admitted to a single center in Egypt N=89
Some concerns
Details

Full description

N/A
Yethindra V, Int J Res Pharm Sci, 2020
Full text
Commentary
No specific funding Umifenovir Standard care RCT Patients with confirmed COVID-19 (mild-moderate) admitted to a single center in Kyrgyzstan N=30
Some concerns
Details

Full description

NCT04311697
Youssef J, SSRN, 2021
Full text
Full text
Commentary
Mixed Aviptadil Placebo RCT Patients with confirmed COVID-19 (severe-critical) admitted to 10 centers in the USA. N=203
Some concerns
Details

Full description

ISRCTN86534580; EudraCT 2020-001209-22
Yu LM, Lancet, 2021
Full text
Full text
Commentary
Commentary
Commentary
Public/non profit Budesonide Standard care RCT Outpatients with suspected or confirmed COVID-19 (symptomatic-mild) treated by multiple centers in the UK N=1073
Some concerns
Details

Full description

ChiCTR2000029431
Yuan X, medRxiv, 2020
Full text
Commentary
Public/non profit Tc-MDP Standard care RCT Patients with confirmed COVID-19 (unclear severity) admitted to 2 centers in China N=21 N/A

Full description

NCT04252885
Yueping L, 2020
Full text
Commentary
Public/non profit Lopinavir-Ritonavir Standard care RCT Patients with confirmed COVID-19 (mild-moderate) admitted to a single center in China. N=86
Some concerns
Details

Full description

Lopinavir-Ritonavir Umifenovir
Lopinavir-Ritonavir Umifenovir
IRCT20200505047318N1
Zarehoseinzade E , Med J Islam Repub Ir, 2021
Full text
Commentary
Public/non profit Finasteride Standard care RCT Patients with suspected or confirmed COVID-19 (unclear severity) admitted to a single center in Iran N=80
Some concerns
Details

Full description

NCT04264533
Zhang J, Ann. Intensive Care, 2021
Full text
Commentary
Public/non profit Vitamin C Placebo RCT Patients with confirmed COVID-19 (severe-critical) admitted to 3 centers in China N=56
Some concerns
Details

Full description

ChiCTR2000030894, NCT04310228
Zhao H, Biomed Pharmacother, 2020
Full text
Commentary
Public/non profit Favipiravir Favipiravir+Tocilizumab RCT Patients with confirmed COVID-19 (moderate-critical) admitted to 4 centers in China N=26
Some concerns
Details

Full description

Tocilizumab Favipiravir+Tocilizumab
Favipiravir Tocilizumab
NCT04333589
Zhao H, Int Immunopharmacol, 2021
Full text
Commentary
Public/non profit Favipiravir Standard care RCT Outpatients whith confirmed recurrent COVID-19 (mild),isolated and treated by 5 centres in China. N=55
Some concerns
Details

Full description

ChiCTR2000029496
Zheng F, 2020
Full text
Commentary
Public/non profit Novaferon+LPV/r Lopinavir-Ritonavir RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in China. N=89
Some concerns
Details

Full description

Novaferon+LPV/r Novaferon
Novaferon Lopinavir-Ritonavir
ChiCTR2000029851
Zhong M, medRxiv, 2020
Full text
Commentary
Private alfa-Lipoic acid Placebo RCT Patients with confirmed COVID-19 (severe-critical) admitted to 1 center in China. N=17
Some concerns
Details

Full description